Filter by Event: IDWeek 2025
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1195
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1214
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1196
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024)
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1313
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1279
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024. Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1287
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1316
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1203
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1319
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022)
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1697
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024)
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1320
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023)
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1340
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1314
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1193
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1317
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1332
In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023
In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1174
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1204
Activity of Aztreonam-Avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019–2024)
Activity of Aztreonam-Avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1315
In vitro Activity of Cefiderocol against Carbapenem-Nonsusceptible Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024)
In vitro Activity of Cefiderocol against Carbapenem-Nonsusceptible Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1286
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1278
In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024
In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1205
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1213
Activity of manogepix against mould isolates from the US collected in 2023
Activity of manogepix against mould isolates from the US collected in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1194
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia (2020–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1318
